Please assess the completion status of the following clinical trial:

Trial Title: Comparison of the Blood Sugar Lowering Effect Between Repaglinide Plus Metformin and Repaglinide Alone in Type 2 Diabetics Not Previously Treated With Oral Sugar-lowering Drugs

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with type 2 diabetes~* Never taken oral antidiabetic drugs before~* HbA1c greater than 8.5 %~* BMI (Body Mass Index) less than or equal to 35 kg/m\^2~Exclusion Criteria:~* Known or suspected allergy to repaglinide, metformin, or any of the excipients in the medications~* Taken an investigational drug in another clinical trial within 4 weeks prior to this trial~* Impaired liver function, defined as ASAT (aspartate aminotransferase) or ALAT (alanine aminotransferase) equal to or greater than 2 times upper normal limit~* Have a clinically significant, active disease of the gastrointestinal, pulmonary, neurological, renal, genitourinary, and haematological systems~* Severe uncontrolled or untreated hypertension (sitting diastolic blood pressure (BP) equal to or greater than 100 mmHg or systolic BP equal to or greater than 180 mmHg)~* Impaired renal function~* Acute or chronic acidosis or if there are plans to have a radiographic material containing iodine~* Have a clinically significant, active cardiovascular disease, or decompensated heart failure~* Treatment with systemic corticosteroids within the past two months prior to screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Repaglinide + metformin (Type: EXPERIMENTAL): Initial dose of repaglinide 1mg plus metformin 500mg once daily. During the dose titration period of 6 weeks, the dose could be titrated up to repaglinide 4 mg and metformin 500 mg three times daily, according to fasting glucose values. The minimal dose was repaglinide 1 mg plus metformin 500 mg three times daily.
- Repaglinide (Type: ACTIVE_COMPARATOR): Initial dose of repaglinide 1 mg three times daily. During the dose titration period of 6 weeks, the dose of repaglinide could be titrated up to 4 mg three times daily, according to fasting glucose values. The minimal dose was repaglinide 1 mg three times daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).